Stay updated with breaking news from Nasdaq Cbay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CymaBay Therapeutics (NASDAQ:CBAY – Get Free Report) had its price objective raised by analysts at BTIG Research from $18.00 to $22.00 in a report released on Friday, Marketbeat reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. BTIG Research’s target price would suggest a potential upside of 63.33% from the stock’s […]
HC Wainwright reissued their buy rating on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a research report report published on Thursday, Benzinga reports. The firm currently has a $19.00 price target on the biopharmaceutical company’s stock. Several other equities research analysts have also recently weighed in on CBAY. StockNews.com cut CymaBay Therapeutics from […]
Guggenheim started coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a report issued on Friday, MarketBeat.com reports. The brokerage issued a buy rating and a $20.00 target price on the biopharmaceutical company’s stock. Several other analysts have also recently issued reports on CBAY. HC Wainwright restated a buy rating and issued a […]
CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Free Report) VP Daniel Menold sold 20,945 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $12.35, for a total value of $258,670.75. The sale was disclosed in a legal filing with the SEC, which […]
CymaBay Therapeutics (NASDAQ:CBAY – Free Report) had its price objective lifted by HC Wainwright from $12.00 to $19.00 in a report released on Tuesday morning, Marketbeat.com reports. They currently have a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for CymaBay Therapeutics’ Q2 2023 earnings at $0.00 EPS, Q4 2023 earnings […]